Stryker Co. (NYSE:SYK) Stock Holdings Lifted by BTC Capital Management Inc.

BTC Capital Management Inc. grew its position in Stryker Co. (NYSE:SYK) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,570 shares of the medical technology company’s stock after acquiring an additional 38 shares during the quarter. BTC Capital Management Inc.’s holdings in Stryker were worth $925,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. AA Financial Advisors LLC increased its holdings in Stryker by 1.3% in the fourth quarter. AA Financial Advisors LLC now owns 3,547 shares of the medical technology company’s stock worth $1,277,000 after buying an additional 46 shares during the last quarter. Evernest Financial Advisors LLC grew its position in Stryker by 4.4% in the fourth quarter. Evernest Financial Advisors LLC now owns 3,271 shares of the medical technology company’s stock worth $1,178,000 after acquiring an additional 139 shares in the last quarter. Norris Perne & French LLP MI increased its stake in shares of Stryker by 3.7% during the 4th quarter. Norris Perne & French LLP MI now owns 2,789 shares of the medical technology company’s stock worth $1,004,000 after purchasing an additional 100 shares during the last quarter. Cibc World Market Inc. raised its holdings in shares of Stryker by 7.1% during the 4th quarter. Cibc World Market Inc. now owns 121,249 shares of the medical technology company’s stock valued at $43,656,000 after purchasing an additional 8,029 shares in the last quarter. Finally, Hixon Zuercher LLC lifted its stake in shares of Stryker by 0.6% in the 4th quarter. Hixon Zuercher LLC now owns 22,216 shares of the medical technology company’s stock valued at $7,999,000 after purchasing an additional 125 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Stock Performance

NYSE SYK opened at $390.48 on Friday. The company has a 50 day moving average of $376.56 and a 200-day moving average of $362.38. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm has a market cap of $148.86 billion, a price-to-earnings ratio of 50.32, a PEG ratio of 2.68 and a beta of 0.95. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.86%. During the same quarter in the previous year, the company earned $3.46 EPS. On average, equities analysts forecast that Stryker Co. will post 13.53 earnings per share for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wells Fargo & Company increased their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday. Stifel Nicolaus increased their price objective on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday. UBS Group boosted their target price on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Evercore ISI increased their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $416.40.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.